Abstract:Current therapeutic options for hearing loss rely on hearing aids, ossiculoplasty or cochlear implants. These devices have limitations, particularly in noisy acoustic environments. Therefore, interest in exploring aetiological treatments to improve not only auditory perception but also the quality of life of those affected is increasing. Gene therapy is a promising aetiological treatment that can fully restore auditory function. The success of gene therapy relies on the efficient delivery of therapeutic genes or genetic modifications to the cells of the inner ear that are designed to repair or replace defective genes and restore normal hearing function. Two main strategies for gene therapy involve the use of recombinant viral vectors and nonviral delivery vehicles. Owing to their excellent diffusion properties and compatibility with sensory cells, recombinant viral vectors, particularly adeno-associated viruses (AAVs), have dominated gene therapy in the cochlea. However, recombinant viral vectors have several drawbacks, such as limited transgene size, immunogenicity (particularly in neonates), and potential need for repeat administration. Nonviral vectors, such as cationic lipids and polymeric nanoparticles, are potential attractive alternatives. Nonviral vectors have several advantages, including low immunogenicity and unlimited transgene size. Recent studies have demonstrated significant auditory recovery in vivo using nonviral vectors in murine models. However, nonviral vectors are not as efficient as viral vectors in transferring genetic material. An alternative to nanoparticles is the use of other methods, such as electroporation. The main advantage of electroporation is that it can be used in combination with cochlear implantation and can target surface cells, but this method has a risk of cell damage. The goal of this review is to provide valuable insights into the current state of research on nonviral vectors for inner ear gene therapy and propose the exploration of innovative and effective gene therapy strategies for the treatment of hearing loss.

Gene Delivery into the Inner Ear and Its Clinical Implications for Hearing and Balance

Exploring delivery systems for targeted nanotechnology-based gene therapy in the inner ear

Molecular Mechanisms and Potentials for Differentiating Inner Ear Stem Cells into Sensory Hair Cells.

Current Status and Prospects of Gene Therapy for the Inner Ear

Potential of Gene and Cell Therapy for Inner Ear Hair Cells

Application of Mesenchymal Stem Cell Therapy and Inner Ear Regeneration for Hearing Loss: A Review

Stem Cell-Based Hair Cell Regeneration and Therapy in the Inner Ear

Stem cell based therapy in the inner ear: appropriate donor cell types and routes for transplantation

Gene therapy: an emerging therapy for hair cells regeneration in the cochlea

An Engineered Three-Dimensional Stem Cell Niche in the Inner Ear by Applying a Nanofibrillar Cellulose Hydrogel with a Sustained-Release Neurotrophic Factor Delivery System

Approaches to Regenerate Hair Cell and Spiral Ganglion Neuron in the Inner Ear

Generation of inner ear cell types from embryonic stem cells.

Stem Cell-Based Therapies in Hearing Loss

Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art

Modeling, applications and challenges of inner ear organoid

Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems

Approaches to Treat Sensorineural Hearing Loss by Hair-Cell Regeneration: The Current State of Therapeutic Developments and Their Potential Impact on Audiological Clinical Practice

Polymer‐Based Nanoparticles for Inner Ear Targeted Trans Differentiation Gene Therapy.

The Biological Strategies for Hearing Re-Establishment Based on the Stem/progenitor Cells

Inner Ear Drug Delivery for Sensorineural Hearing Loss: Current Challenges and Opportunities

Current advances in biomaterials for inner ear cell regeneration